We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaborat... Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single in-office intravitreal IVT injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust sustained treatment response reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor VEGF injections. Show more
REDWOOD CITY, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on September 3, 2024, the Compensation Committee of Adverumβs Board of...
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
- 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar...
REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.19 | 2.66106442577 | 7.14 | 7.67 | 6.9 | 137288 | 7.17727944 | CS |
4 | 0.38 | 5.46762589928 | 6.95 | 7.67 | 6.54 | 146749 | 7.08434286 | CS |
12 | 0.49 | 7.16374269006 | 6.84 | 10.14 | 6.39 | 326264 | 7.5755502 | CS |
26 | -9.87 | -57.3837209302 | 17.2 | 18 | 6.38 | 367134 | 10.01189085 | CS |
52 | -6.77 | -48.0141843972 | 14.1 | 29.8 | 6.38 | 754498 | 15.60077928 | CS |
156 | -15.27 | -67.5663716814 | 22.6 | 29.8 | 5.31 | 854268 | 15.05130099 | CS |
260 | -54.87 | -88.2154340836 | 62.2 | 269.8 | 5.31 | 1124431 | 56.4545904 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions